Luigi Celio

List of Publications by Year in descending order

74 papers	2,194 citations	361045 20 h-index	253896 43 g-index
74 all docs	74 docs citations	74 times ranked	2170 citing authors

#	Article	IF	Citations
1	Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data. Oncologist, 2021, 26, e1073-e1082.	1.9	20
2	Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study. Oncologist, 2021, 26, e1854-e1861.	1.9	16
3	Everyâ€otherâ€day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the â€œRete Ematologica Pugliese†. Cancer Medicine, 2020, 9, 170-178.	1.3	4
4	A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer. International Journal of Cancer, 2020, 146, 3495-3503.	2.3	17
5	Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study. BMC Cancer, 2020, 20, 232.	1.1	6
6	Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer. Cancers, 2020, 12, 617.	1.7	4
7	A new standard prophylaxis for emesis caused by cisplatin?. Lancet Oncology, The, 2020, 21, e128.	5.1	0
8	One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis. Oncologist, 2019, 24, 1593-1600.	1.9	21
9	Neurokinin-1 receptor antagonists: review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults. Expert Review of Clinical Pharmacology, 2019, 12, 661-680.	1.3	18
10	Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. Critical Reviews in Oncology/Hematology, 2019, 139, 53-66.	2.0	137
11	Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study. Tumori, 2019, 105, 253-258.	0.6	5
12	Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence. BMC Cancer, 2019, 19, 1268.	1.1	24
13	Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles. Clinical Breast Cancer, 2019, 19, e306-e318.	1.1	16
14	A novel subpopulation of circulating tumor cells in patients with cholangiocarcinoma.. Journal of Clinical Oncology, 2019, 37, e15637-e15637.	0.8	1
15	Abstract 1390: Molecular characterization of circulating tumor cells in cholangiocarcinoma patients: A new tool for treatment management. , 2019, , .		0
16	Is the Dexamethasone-Sparing Strategy Ready For Cisplatin? Too Early For an Answer. Journal of Clinical Oncology, 2018, 36, 2741-2742.	0.8	7
17	Pro-netupitant/palonosetron (IV) for the treatment of radio-and-chemotherapy-induced nausea and vomiting. Expert Opinion on Pharmacotherapy, 2018, 19, 1267-1277.	0.9	3
18	Pre-Chemotherapy Levels of Hemostatic Biomarkers and Prediction of Prognosis in Newly Diagnosed Metastatic Cancer Patients from the Hypercan Study. Blood, 2018, 132, 3795-3795.	0.6	0

#	Article	IF	Citations
19	Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy. BMJ Open, 2017, 7, e015645.	0.8	13
20	2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. Supportive Care in Cancer, 2017, 25, 277-288.	1.0	103
21	Systematic review and individual patient data based meta-analysis of palonosetron trials for chemotherapy induced nausea and vomiting.. Journal of Clinical Oncology, 2017, 35, e21688-e21688.	0.8	0
22	Prevention of CINV in Patients Receiving High-Dose Multiple-Day Chemotherapy. , 2016, , 135-156.		0
23	Should clinicians always administer dexamethasone beyond 24Âh after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies. Supportive Care in Cancer, 2016, 24, 1025-1034.	1.0	4
24	Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy. Core Evidence, 2015, 10, 75.	4.7	18
25	Measurement of Thrombin Generation Is a Positive Predictive Biomarker of V enous Thromboembolism (VTE) in Metastatic Cancer Patients Enrolled in the Hypercan Study. Blood, 2015, 126, 654-654.	0.6	2
26	Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy. Future Oncology, 2014, 10, 2569-2578.	1.1	8
27	Aprepitant Versus Dexamethasone for Delayed Emesis: What Is the Role of the 5-Hydroxytryptamine Type 3 Receptor Antagonist Palonosetron?. Journal of Clinical Oncology, 2014, 32, 2185-2186.	0.8	3
28	Hypercoagulation Screening As a Marker of Thrombosis and Poor Disease Prognosis in Cancer Patients: The Hypercan Prospective Study. Blood, 2014, 124, 586-586.	0.6	2
29	Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials. Supportive Care in Cancer, 2013, 21, 565-573.	1.0	25
30	Palonosetron plus dexamethasone in highly emetogenic chemotherapy: pooled data from two Phase III trials. Future Oncology, 2013, 9, 1451-1458.	1.1	7
31	Research on Chemotherapy-Induced Nausea: Back to the Past for an Unmet Need?. Journal of Clinical Oncology, 2013, 31, 1376-1377.	0.8	9
32	Is a Dexamethasone-Sparing Strategy Capable of Preventing Acute and Delayed Emesis Caused by Combined Doxorubicin and Paclitaxel for Breast Cancer Analysis of a Phase II Trial. Oncology, 2013, 84, 371-377.	0.9	3
33	Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting. Patient Preference and Adherence, 2013, 7, 391.	0.8	17
34	Palonosetron Plus 1-Day Dexamethasone for the Prevention of Nausea and Vomiting Due to Moderately Emetogenic Chemotherapy: Effect of Established Risk Factors on Treatment Outcome in a Phase III Trial. The Journal of Supportive Oncology, 2012, 10, 65-71.	2.3	18
35	Palonosetron: An Evidence-Based Choice in Prevention of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy. Tumori, 2012, 98, 279-286.	0.6	3
36	Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Tumori, 2012, 98, 279-86.	0.6	4

#	Article	IF	Citations
37	Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Supportive Care in Cancer, 2011, 19, 1217-1225.	1.0	96
38	Feasibility Study of Biweekly Capecitabine, Oxaliplatin, and Irinotecan in Patients with Untreated Advanced Gastric Cancer. Tumori, 2009, 95, 43-47.	0.6	9
39	Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. Annals of Oncology, 2009, 20, 1062-1067.	0.6	18
40	Single-Institution Series of Early-Stage Merkel Cell Carcinoma: Long-Term Outcomes in 95 Patients Managed with Surgery Alone. Annals of Surgical Oncology, 2009, 16, 2985-2993.	0.7	50
41	Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron. Cancer Management and Research, 2009, 1, 89-97.	0.9	1
42	Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer. Endocrine-Related Cancer, 2008, 15, 439-449.	1.6	16
43	Clinical Update on Palonosetron in the Management of Chemotherapy-Induced Nausea and Vomiting. Tumori, 2008, 94, 447-452.	0.6	12
44	Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting. Tumori, 2008, 94, 447-52.	0.6	7
45	Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Annals of Oncology, 2007, 18, 1810-1816.	0.6	34
46	Neuroendocrine Tumors of the Larynx: A Clinical Report and Literature Review. Tumori, 2006, 92, 72-75.	0.6	17
47	Safety and Efficacy of Two Different Doses of Capecitabine in the Treatment of Advanced Breast Cancer in Older Women. Journal of Clinical Oncology, 2005, 23, 2155-2161.	0.8	200
48	Prospective evaluation of estrogen receptor-Î² in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients. Endocrine-Related Cancer, 2004, 11, 761-770.	1.6	25
49	Acute confusional state with fatal outcome in a cancer patient. Neurological Sciences, 2004, 24, 424-425.	0.9	0
50	Phase II study of pemetrexed disodium (AlimtaÂ®) administered with oral folic acid in patients with advanced gastric cancer. Annals of Oncology, 2003, 14, 1543-1548.	0.6	51
51	Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole?. International Journal of Oncology, 2003, 22, 1081.	1.4	3
52	Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Annals of Oncology, 2002, 13, 614-621.	0.6	103
53	Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology, 2002, 80, 411-418.	1.2	11
54	Pemetrexed in gastric cancer: Clinical experience and future perspectives. Seminars in Oncology, 2002, 29, 63-68.	0.8	19

#	Article	IF	Citations
55	Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial. Journal of Clinical Oncology, 2000, 18, 2234-2244.	0.8	302
56	Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors. Annals of Oncology, 2000, 11, 1017-1022.	0.6	31
57	Ovarian Ablation for Premenopausal Early-Stage Breast Cancer: An Update. Tumori, 2000, 86, 191-194.	0.6	4
58	Adjuvant Oophorectomy versus CMF in Premenopausal Node-Positive Breast Cancer: Long-Term Results of an Experience at the Milan Cancer Institute. Tumori, 2000, 86, 258-259.	0.6	2
59	The luteinising hormoneâ€“releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers. Journal of Steroid Biochemistry and Molecular Biology, 2000, 75, 65-73.	1.2	7
60	Fluoropyrimidines in the Treatment of Advanced Neoplastic Diseases: Role and Advantages of UFT. Tumori, 1999, 85, 6-11.	0.6	8
61	Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. , 1999, 86, 858-865.		249
62	Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los Angeles, U.S.A.1. European Journal of Cancer, 1999, 35, 208-213.	1.3	65
63	The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels. Journal of Steroid Biochemistry and Molecular Biology, 1997, 63, 261-267.	1.2	33
64	Novel Non-Steroidal Aromatase Inhibitors: Are There New Perspectives in the Treatment of Breast Cancer?. Tumori, 1996, 82, 417-422.	0.6	11
65	Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. British Journal of Cancer, 1995, 71, 1111-1114.	2.9	15
66	Formestane as Treatment of Advanced Breast Cancer in Elderly Women. Tumori, 1994, 80, 433-437.	0.6	7
67	Effect of two 4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancer. Breast Cancer Research and Treatment, 1994, 30, 127-132.	1.1	14
68	Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer. British Journal of Cancer, 1994, 70, 145-150.	2.9	26
69	Goserelin in Premenopausal Advanced Breast Cancer: Clinical and Endocrine Evaluation of Responsive Patients. Oncology, 1994, 51, 262-269.	0.9	19
70	Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a: A study by the Italian trials in Medical Oncology Group. Cancer, 1993, 72, 3099-3105.	2.0	121
71	Efficacy and tolerability of 4-hydroxyandrostenedione (4-OHA) as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy. Cancer Treatment Reviews, 1993, 19, 31-36.	3.4	15
72	Salvage Treatment After rInterferon Î±-2a in Advanced Neuroendocrine Tumors. Acta OncolÃ³gica, 1993, 32, 245-250.	0.8	20

#	Article	IF	Citations
73	Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer-and lymphokine-activated-killer-mediated cytotoxicity. Cancer Immunology, Immunotherapy, 1992, 34, 272-278.	2.0	8
74	Verapamil upregulates sensitivity of human colon and breast cancer cells to LAK-cytotoxicity in vitro. European Journal of Cancer & Clinical Oncology, 1991, 27, 1393-1395.	0.9	27